{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:07:50Z","timestamp":1776413270142,"version":"3.51.2"},"reference-count":86,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kopchick Translational Research Fund"},{"DOI":"10.13039\/100008076","name":"Ohio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#R21AG081962"],"award-info":[{"award-number":["#R21AG081962"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The binding of human growth hormone (hGH) to the human growth hormone receptor (hGHR) is a key endocrinological process that controls critical aspects of cell growth, proliferation, and differentiation. Mechanistically, this sequential, asymmetric binding event involves the interaction between a single hGH molecule and distinct sites (sites 1 and 2) on the extracellular domain of a preformed hGHR homodimer. Our group recently identified S1H, a rationally designed peptide sequence mimetic of the hGH site 1-binding helix (residues 36-51) that disrupts the hGH-hGHR interaction and inhibits hGH-mediated phosphorylation of signal transducer and activator of transcription 5 (STAT5) in hGHR-positive cell lines. Structure\u2013activity relationship studies revealed a positive correlation between helical propensity and inhibitory potency of the S1H peptide, prompting the design of structurally \u201cstabilized\u201d S1H variants (SS1H) with improved biological activity. In this study, we employed a chemical strategy, termed hydrocarbon stapling, to generate a series of SS1H peptides that proved to be more helical, proteolytically stable, and biologically active compared to linear (unstructured) S1H. Notably, one SS1H derivative (SS1HB) inhibited hGH-induced STAT5 phosphorylation in hGHR-positive human bladder cancer cells more effectively than pegvisomant, the only hGHR antagonist currently approved by the FDA. Collectively, our results demonstrate that hydrocarbon stapling improves the antagonistic effects of S1H peptides and elevates their potential as chemical probes to study the molecular mechanisms of hGH signaling. It is also anticipated that SS1H peptides will serve as potent lead compounds for developing next-generation therapeutics designed to treat endocrine disorders that manifest along the hGH-hGHR signaling axis.<\/jats:p>","DOI":"10.1210\/endocr\/bqag022","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:37:51Z","timestamp":1771936671000},"source":"Crossref","is-referenced-by-count":0,"title":["A helical peptide antagonist of the human growth hormone receptor"],"prefix":"10.1210","volume":"167","author":[{"given":"Khairun","family":"Nahar","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-1356","authenticated-orcid":false,"given":"Reetobrata","family":"Basu","sequence":"additional","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Institute for Molecular Medicine and Aging, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Institute for Molecular Medicine and Aging, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Translational Biomedical Sciences Program, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A","family":"Pettis","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Ohio University Honors Tutorial College, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udani","family":"Gamage","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Molecular and Cellular Biology Program, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-1277","authenticated-orcid":false,"given":"Justin M","family":"Holub","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Institute for Molecular Medicine and Aging, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Molecular and Cellular Biology Program, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2177","authenticated-orcid":false,"given":"John J","family":"Kopchick","sequence":"additional","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Institute for Molecular Medicine and Aging, Ohio University , Athens, OH 45701 ,","place":["USA"]},{"name":"Molecular and Cellular Biology Program, Ohio University , Athens, OH 45701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"9","key":"2026041703262674900_bqag022-B1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrendo.2010.123","article-title":"The growth hormone receptor: mechanism of activation and clinical implications","volume":"6","author":"Brooks","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026041703262674900_bqag022-B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-019-0036-y","article-title":"Targeting growth hormone function: strategies and therapeutic applications","volume":"4","author":"Lu","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2026041703262674900_bqag022-B3","first-page":"1021","article-title":"The cardiovascular system in growth hormone excess and growth hormone deficiency","volume":"35","author":"Lombardi","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2026041703262674900_bqag022-B4","doi-asserted-by":"crossref","first-page":"e220402","DOI":"10.1530\/ERC-22-0402","article-title":"Cancer in growth hormone excess and growth hormone deficit","volume":"30","author":"Guevara-Aguirre","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026041703262674900_bqag022-B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf579","article-title":"Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment","author":"Biller","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026041703262674900_bqag022-B6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"11","key":"2026041703262674900_bqag022-B7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026041703262674900_bqag022-B8","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae033","article-title":"A potent neutralizing monoclonal antibody to human growth hormone suppresses insulin-like growth factor-1 in female rats","volume":"165","author":"Hata","year":"2024","journal-title":"Endocrinology"},{"issue":"1","key":"2026041703262674900_bqag022-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1568005310202010027","article-title":"Clinical pharmacology of human growth hormone and its secretagogues","volume":"2","author":"Root","year":"2002","journal-title":"Curr Drug Targets Immune Endocr Metab Disord"},{"key":"2026041703262674900_bqag022-B10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fendo.2018.00035","article-title":"The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects","volume":"9","author":"Dehkhoda","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5042","key":"2026041703262674900_bqag022-B11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1549776","article-title":"Human growth hormone and extracellular domain of its receptor: crystal structure of the complex","volume":"255","author":"De Vos","year":"1992","journal-title":"Science"},{"issue":"6185","key":"2026041703262674900_bqag022-B12","doi-asserted-by":"crossref","first-page":"1249783","DOI":"10.1126\/science.1249783","article-title":"Mechanism of activation of protein kinase JAK2 by the growth hormone receptor","volume":"344","author":"Brooks","year":"2014","journal-title":"Science"},{"issue":"9","key":"2026041703262674900_bqag022-B13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nsmb977","article-title":"Model for growth hormone receptor activation based on subunit rotation within a receptor dimer","volume":"12","author":"Brown","year":"2005","journal-title":"Nat Struct Mol Biol"},{"issue":"34","key":"2026041703262674900_bqag022-B14","doi-asserted-by":"crossref","first-page":"21709","DOI":"10.1016\/S0021-9258(17)31863-X","article-title":"Domains of the growth hormone receptor required for association and activation of JAK2 tyrosine kinase","volume":"269","author":"VanderKuur","year":"1994","journal-title":"J Biol Chem"},{"issue":"7","key":"2026041703262674900_bqag022-B15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/me.2014-1099","article-title":"Minireview: mechanisms of growth hormone-mediated gene regulation","volume":"28","author":"Chia","year":"2014","journal-title":"Mol Endocrinol"},{"issue":"1","key":"2026041703262674900_bqag022-B16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT \u2013 emerging players in metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"2026041703262674900_bqag022-B17","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1074\/jbc.271.12.6708","article-title":"Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization","volume":"271","author":"Harding","year":"1996","journal-title":"J Biol Chem"},{"issue":"4","key":"2026041703262674900_bqag022-B18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/jc.2002-022049","article-title":"Growth hormone receptor antagonists","volume":"89","author":"Muller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026041703262674900_bqag022-B19","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1210\/endo-115-5-1805","article-title":"Monoclonal antibodies to the rabbit liver growth hormone receptor: production and characterization","volume":"115","author":"Barnard","year":"1984","journal-title":"Endocrinology"},{"issue":"8","key":"2026041703262674900_bqag022-B20","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1073\/pnas.88.8.3407","article-title":"Rational design of receptor-specific variants of human growth hormone","volume":"88","author":"Cunningham","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026041703262674900_bqag022-B21","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1210\/me.2004-0102","article-title":"A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis","volume":"18","author":"Jiang","year":"2004","journal-title":"Mol Endocrinol"},{"key":"2026041703262674900_bqag022-B22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ijbiomac.2015.05.039","article-title":"Development and characterization of a novel GHR antibody antagonist, GF185","volume":"79","author":"Sun","year":"2015","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"2026041703262674900_bqag022-B23","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocr Rev"},{"issue":"1","key":"2026041703262674900_bqag022-B24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1677\/jme.0.0290011","article-title":"Pegvisomant: structure and function","volume":"29","author":"Pradhananga","year":"2002","journal-title":"J Mol Endocrinol"},{"issue":"13","key":"2026041703262674900_bqag022-B25","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1073\/pnas.87.13.5061","article-title":"Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice","volume":"87","author":"Chen","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026041703262674900_bqag022-B26","doi-asserted-by":"crossref","first-page":"105030","DOI":"10.1016\/j.jbc.2023.105030","article-title":"Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with site-specific PEG conjugates","volume":"299","author":"Basu","year":"2023","journal-title":"J Biol Chem"},{"issue":"4","key":"2026041703262674900_bqag022-B27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/17446651.1.4.489","article-title":"Pegvisomant therapy for acromegaly","volume":"1","author":"Freda","year":"2006","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"16","key":"2026041703262674900_bqag022-B28","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041703262674900_bqag022-B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11102-016-0753-y","article-title":"Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly","volume":"20","author":"Tritos","year":"2017","journal-title":"Pituitary"},{"key":"2026041703262674900_bqag022-B30","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.jbc.2021.100588","article-title":"A novel peptide antagonist of the human growth hormone receptor","volume":"296","author":"Basu","year":"2021","journal-title":"J Biol Chem"},{"issue":"4","key":"2026041703262674900_bqag022-B31","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1210\/clinem\/dgad568","article-title":"New treatments for acromegaly in development","volume":"109","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2026041703262674900_bqag022-B32","doi-asserted-by":"crossref","first-page":"A511","DOI":"10.1210\/jendso\/bvac150.1062","article-title":"ODP353 sustained suppression of IGF1 with AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor and a potential new treatment for acromegaly","volume":"6","author":"Culler","year":"2022","journal-title":"J Endocr Soc"},{"key":"2026041703262674900_bqag022-B33","first-page":"P148","article-title":"AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly","volume":"81","author":"Milano","year":"2022","journal-title":"Endocr Abstr"},{"issue":"2","key":"2026041703262674900_bqag022-B34","doi-asserted-by":"crossref","first-page":"e70001","DOI":"10.1002\/jmr.70001","article-title":"Inhibitory potential and binding thermodynamics of scyllatoxin-based BH3 domain mimetics targeting repressor BCL2 proteins","volume":"38","author":"Amarasiri","year":"2025","journal-title":"J Mol Recognit"},{"issue":"3","key":"2026041703262674900_bqag022-B35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nchem.1568","article-title":"Inhibition of \u03b1-helix-mediated protein-protein interactions using designed molecules","volume":"5","author":"Azzarito","year":"2013","journal-title":"Nat Chem"},{"issue":"6","key":"2026041703262674900_bqag022-B36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ddr.21408","article-title":"Small scaffolds, big potential: developing miniature proteins as therapeutic agents","volume":"78","author":"Holub","year":"2017","journal-title":"Drug Dev Res"},{"issue":"10","key":"2026041703262674900_bqag022-B37","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3390\/ijms20102383","article-title":"A comprehensive review on current advances in peptide drug development and design","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026041703262674900_bqag022-B38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11095-023-03486-0","article-title":"Strategies to improve the physicochemical properties of peptide-based drugs","volume":"40","author":"Lee","year":"2023","journal-title":"Pharm Res"},{"issue":"1","key":"2026041703262674900_bqag022-B39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1472-6823-9-20","article-title":"Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation","volume":"9","author":"Moore","year":"2009","journal-title":"BMC Endocr Disord"},{"issue":"23","key":"2026041703262674900_bqag022-B40","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1002\/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.0.CO;2-V","article-title":"Highly efficient synthesis of covalently cross-linked peptide helices by ring-closing metathesis","volume":"37","author":"Blackwell","year":"1998","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"2026041703262674900_bqag022-B41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nprot.2011.324","article-title":"Synthesis of all-hydrocarbon stapled \u03b1-helical peptides by ring-closing olefin metathesis","volume":"6","author":"Kim","year":"2011","journal-title":"Nat Protoc"},{"issue":"24","key":"2026041703262674900_bqag022-B42","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1021\/ja000563a","article-title":"An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides","volume":"122","author":"Schafmeister","year":"2000","journal-title":"J Am Chem Soc"},{"issue":"50","key":"2026041703262674900_bqag022-B43","doi-asserted-by":"crossref","first-page":"32197","DOI":"10.1074\/jbc.271.50.32197","article-title":"Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution","volume":"271","author":"Sundstr\u00f6m","year":"1996","journal-title":"J Biol Chem"},{"issue":"4","key":"2026041703262674900_bqag022-B44","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1039\/b919671d","article-title":"Helix propensities of conformationally restricted amino acids. Non-natural substitutes for helix breaking proline and helix forming alanine","volume":"8","author":"Al\u00edas","year":"2010","journal-title":"Org Biomol Chem"},{"issue":"11","key":"2026041703262674900_bqag022-B45","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/bip.360321104","article-title":"Flexible-geometry conformational energy maps for the amino acid residue preceding a proline","volume":"32","author":"Hurley","year":"1992","journal-title":"Biopolymers"},{"issue":"3","key":"2026041703262674900_bqag022-B46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1399-3011.1990.tb00939.x","article-title":"Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids","volume":"35","author":"Fields","year":"1990","journal-title":"Int J Pept Protein Res"},{"key":"2026041703262674900_bqag022-B47","doi-asserted-by":"crossref","first-page":"e3337","DOI":"10.1002\/psc.3337","article-title":"N-terminal acetylation of antimicrobial peptide L163 improves its stability against protease degradation","volume":"27","author":"Li","year":"2021","journal-title":"J Pept Sci"},{"issue":"7","key":"2026041703262674900_bqag022-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0116-z","article-title":"Spotlight on protein N-terminal acetylation","volume":"50","author":"Ree","year":"2018","journal-title":"Exp Mol Med"},{"key":"2026041703262674900_bqag022-B49","unstructured":"Nahar K, Basu R, Ahmad A, et al \u00a0Supplementary information. Figshare. 2026. https:\/\/figshare.com\/s\/63d84854420da4b732ab"},{"issue":"2","key":"2026041703262674900_bqag022-B50","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0006-291X(90)90755-C","article-title":"Conformation of proline residues in bacteriorhodopsin","volume":"172","author":"Deber","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"issue":"37","key":"2026041703262674900_bqag022-B51","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1021\/bi00101a001","article-title":"Proline residues in transmembrane helixes: structural or dynamic role?","volume":"30","author":"Williams","year":"1991","journal-title":"Biochemistry"},{"key":"2026041703262674900_bqag022-B52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0076-6879(08)01622-4","article-title":"Synthesis and biophysical characterization of stabilized \u03b1-helices of BCL-2 domains","volume":"446","author":"Bird","year":"2008","journal-title":"Methods Enzymol"},{"issue":"32","key":"2026041703262674900_bqag022-B53","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1073\/pnas.1002713107","article-title":"Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic","volume":"107","author":"Bird","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026041703262674900_bqag022-B54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"2026041703262674900_bqag022-B55","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/pro.3352","article-title":"Global substrate specificity profiling of post-translational modifying enzymes","volume":"27","author":"Ivry","year":"2018","journal-title":"Protein Sci"},{"issue":"5689","key":"2026041703262674900_bqag022-B56","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1099191","article-title":"Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix","volume":"305","author":"Walensky","year":"2004","journal-title":"Science"},{"issue":"1","key":"2026041703262674900_bqag022-B57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00726-025-03454-5","article-title":"Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Amino Acids"},{"issue":"15","key":"2026041703262674900_bqag022-B58","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.3390\/ijms26157113","article-title":"Growth hormone signaling in bladder cancer: transcriptomic profiling of patient samples and in vitro evidence of therapy resistance via ABC transporters and EMT activation","volume":"26","author":"Davis","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026041703262674900_bqag022-B59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","article-title":"New insights into protein-protein interaction modulators in drug discovery and therapeutic advance","volume":"9","author":"Nada","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026041703262674900_bqag022-B60","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2012.10","article-title":"Features of protein\u2013protein interactions that translate into potent inhibitors: topology, surface area and affinity","volume":"14","author":"Smith","year":"2012","journal-title":"Expert Rev Mol Med"},{"issue":"23","key":"2026041703262674900_bqag022-B61","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/cbic.202000495","article-title":"Chemical proteomics for expanding the druggability of human disease","volume":"21","author":"Zhang","year":"2020","journal-title":"Chembiochem Eur J Chem Biol"},{"key":"2026041703262674900_bqag022-B62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.sbi.2016.12.009","article-title":"Peptides and peptidomimetics as regulators of protein-protein interactions","volume":"44","author":"Cunningham","year":"2017","journal-title":"Curr Opin Struct Biol"},{"issue":"4","key":"2026041703262674900_bqag022-B63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12551-019-00570-x","article-title":"Protein\u2013protein interaction modulators: advances, successes and remaining challenges","volume":"11","author":"Mabonga","year":"2019","journal-title":"Biophys Rev"},{"key":"2026041703262674900_bqag022-B64","doi-asserted-by":"crossref","first-page":"e3627","DOI":"10.1002\/psc.3627","article-title":"FDA's stamp of approval: unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond","volume":"30","author":"Al Musaimi","year":"2024","journal-title":"J Pept Sci"},{"key":"2026041703262674900_bqag022-B65","doi-asserted-by":"crossref","first-page":"171404","DOI":"10.1016\/j.peptides.2025.171404","article-title":"Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery\u22c6","volume":"188","author":"J\u00fclke","year":"2025","journal-title":"Peptides"},{"issue":"7976","key":"2026041703262674900_bqag022-B66","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"issue":"1","key":"2026041703262674900_bqag022-B67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40364-025-00758-2","article-title":"Integrating artificial intelligence in drug discovery and early drug development: a transformative approach","volume":"13","author":"Ocana","year":"2025","journal-title":"Biomark Res"},{"issue":"1","key":"2026041703262674900_bqag022-B68","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u2018undruggable\u2019 proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2026041703262674900_bqag022-B69","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"2026041703262674900_bqag022-B70","first-page":"1","article-title":"Peptides as drug candidates: limitations and recent development perspectives","volume":"8","author":"Haggag","year":"2018","journal-title":"Biomed J Sci Tech Res"},{"key":"2026041703262674900_bqag022-B71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/B978-0-08-100736-5.00008-9","volume-title":"Peptide Applications in Biomedicine, Biotechnology and Bioengineering","author":"Wetzler","year":"2018"},{"issue":"2","key":"2026041703262674900_bqag022-B72","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.drudis.2017.10.016","article-title":"Interfering peptides targeting protein\u2013protein interactions: the next generation of drugs?","volume":"23","author":"Bruzzoni-Giovanelli","year":"2018","journal-title":"Drug Discov Today"},{"issue":"1","key":"2026041703262674900_bqag022-B73","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J"},{"issue":"21","key":"2026041703262674900_bqag022-B74","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov Today"},{"issue":"9","key":"2026041703262674900_bqag022-B75","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00726-020-02890-9","article-title":"Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics","volume":"52","author":"Ding","year":"2020","journal-title":"Amino Acids"},{"issue":"12","key":"2026041703262674900_bqag022-B76","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1021\/acs.bioconjchem.6b00502","article-title":"Engineering an affinity-enhanced peptide through optimization of cyclization chemistry","volume":"27","author":"Ngambenjawong","year":"2016","journal-title":"Bioconjug Chem"},{"issue":"3","key":"2026041703262674900_bqag022-B77","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2026041703262674900_bqag022-B78","doi-asserted-by":"crossref","first-page":"1353626","DOI":"10.3389\/fphar.2024.1353626","article-title":"Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"issue":"11","key":"2026041703262674900_bqag022-B79","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40262-025-01568-3","article-title":"PEGylated proteins: how much does molecular weight matter?","volume":"64","author":"Fornasari","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026041703262674900_bqag022-B80","doi-asserted-by":"crossref","first-page":"116488","DOI":"10.1016\/j.jpba.2024.116488","article-title":"Cyclic peptides: a powerful instrument for advancing biomedical nanotechnologies and drug development","volume":"252","author":"Martian","year":"2025","journal-title":"J Pharm Biomed Anal"},{"key":"2026041703262674900_bqag022-B81","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/psc.491","article-title":"The cyclization of peptides and depsipeptides","volume":"9","author":"Davies","year":"2003","journal-title":"J Pept Sci"},{"issue":"1-2","key":"2026041703262674900_bqag022-B82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov Today"},{"issue":"3","key":"2026041703262674900_bqag022-B83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/9780470559277.ch110042","article-title":"Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic targeting","volume":"3","author":"Bird","year":"2011","journal-title":"Curr Protoc Chem Biol"},{"issue":"4","key":"2026041703262674900_bqag022-B84","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/aivt.2016.0026","article-title":"Perspectives on in vitro to in vivo extrapolations","volume":"4","author":"Hartung","year":"2018","journal-title":"Appl Vitro Toxicol"},{"key":"2026041703262674900_bqag022-B85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cotox.2020.09.001","article-title":"In vitro to in vivo translation","volume":"23-24","author":"Mattes","year":"2020","journal-title":"Curr Opin Toxicol"},{"issue":"1-2","key":"2026041703262674900_bqag022-B86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2013.09.004","article-title":"Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications","volume":"386","author":"Kopchick","year":"2014","journal-title":"Mol Cell Endocrinol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag022\/67124619\/bqag022.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/4\/bqag022\/68099725\/bqag022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/4\/bqag022\/68099725\/bqag022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:26:47Z","timestamp":1776410807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag022\/8498921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag022","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,26]]},"article-number":"bqag022"}}